Since the MAPK and NF-κB pathways are highly mutated or deregulated in GBM, we hypothesized that the association of TMZ with an inhibitor of TAK1 (5Z-7-oxozeaenol) could enhance the sensitivity of glioblastoma cells to chemotherapy treatment with TMZ; a second step, aimed to validate the involvement of TAK1 in GMB patients treated with TMZ. This evidence concerns the gene NFKB1 and glioblastoma.